Adaptimmune Therapeutics PLC (ADAP)
0.6616
+0.02
(+3.93%)
USD |
NASDAQ |
Nov 22, 16:00
0.66
0.00 (0.00%)
After-Hours: 20:00
Adaptimmune Therapeutics Cash from Financing (Quarterly): 25.00M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 25.00M |
| June 30, 2024 | 24.51M |
| March 31, 2024 | 29.24M |
| December 31, 2023 | 0.074M |
| September 30, 2023 | 0.596M |
| June 30, 2023 | 0.014M |
| March 31, 2023 | 0.196M |
| December 31, 2022 | 1.403M |
| September 30, 2022 | 1.452M |
| June 30, 2022 | 9.977M |
| March 31, 2022 | 0.035M |
| December 31, 2021 | 0.052M |
| September 30, 2021 | 0.139M |
| June 30, 2021 | 2.563M |
| March 31, 2021 | 0.534M |
| December 31, 2020 | 0.122M |
| September 30, 2020 | 0.466M |
| June 30, 2020 | 248.02M |
| March 31, 2020 | 91.44M |
| Date | Value |
|---|---|
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.33M |
| March 31, 2019 | 0.036M |
| December 31, 2018 | 0.104M |
| September 30, 2018 | 100.16M |
| June 30, 2018 | 0.89M |
| March 31, 2018 | 1.534M |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.37M |
| June 30, 2017 | 41.80M |
| March 31, 2017 | 61.40M |
| December 31, 2016 | 0.017M |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| September 30, 2015 | 0.00 |
| December 31, 2014 | -4.093M |
| September 30, 2014 | 98.34M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
Dec 2019
248.02M
Maximum
Jun 2020
21.79M
Average
0.565M
Median
Cash from Financing (Quarterly) Benchmarks
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | -0.0888M |
| Autolus Therapeutics PLC | 0.185M |
| TC BioPharm (Holdings) PLC | 1.183M |
| Verona Pharma PLC | -7.087M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -54.45M |
| Cash from Investing (Quarterly) | -66.02M |
| Free Cash Flow | -56.05M |
| Free Cash Flow Per Share (Quarterly) | -0.2146 |
| Free Cash Flow to Equity (Quarterly) | -79.80M |
| Free Cash Flow to Firm (Quarterly) | -54.89M |
| Free Cash Flow Yield | -34.41% |